



شبكة المعلومات الجامعية

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ



شبكة المعلومات الجامعية  
@ ASUNET



# شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم





شبكة المعلومات الجامعية

# جامعة عين شمس

التوثيق الالكتروني والميكرو فيلم

## قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها  
علي هذه الأفلام قد أعدت دون أية تغيرات



## يجب أن

تحفظ هذه الأفلام بعيدا عن الغبار

في درجة حرارة من ١٥-٢٥ مئوية ورطوبة نسبية من ٢٠-٤٠%

To be Kept away from Dust in Dry Cool place of  
15-25- c and relative humidity 20-40%

# بعض الوثائق الأصلية تالفة

# بالرسالة صفحات لم ترد بالاصل



---

**In Vitro sensitivity profile of some  
new chemotherapeutic agents in  
bilharzial related bladder cancer**



THESIS  
Submitted in partial Fulfillment  
For The Degree Of M.Sc.  
In Zoology  
Cytology, Histology and Genetics

By  
**Ayman Mohamed Metwally**  
National Cancer Institute  
Cairo University

To  
Zoology Department  
Faculty Of Science  
Cairo University

**2000**

---

# **APPROVAL SHEET**

*Title of the M. Sc. Thesis*

***In vitro sensitivity profile of some new  
chemotherapeutic agents in bilharzial  
related bladder cancer***

**Name of Candidate**

***Ayman Mohamed Metwally***

**Submitted to the faculty of Science,  
Cairo University  
Zoology Department**

## **Supervision Committee**

1) Prof. Dr. Mohamed Akmal Abd El – Rehiem El – Ghor .

2) Prof. Dr. Hussein Mostafa Khaled.

3) Prof. Dr. Mostafa Raafat Mahmoud.

***H.M. Khaled***

***M. Raafat***

***Head of Zoology Department***

***Prof. Dr. Kamal S. Al – Badry***

---

## **ACKNOWLEDGEMENT**

**T**o begin with, I feel always indebted to Allah the most kind and merciful.

For **Prof. Dr. Akmal Abd El-Rehim El-Ghor**, Prof. of genetics, Zoology Department, Cairo university, no words can satisfy and explain my deep feeling of gratitude for his help, suggestions and encouragement throughout the work.

My very special to **Prof. Dr. Hussein Mostafa Khaled**, Prof. Dr. in the National Cancer Institute, for his suggestions and valuable help in this work.

I would like to express my deepest gratitude and thanks to **Prof. Dr. Mostafa Rafaat Mahmoud**, Prof. Dr. in the National Cancer Institute, for his careful supervision and his advise.

---



---

## **ABSTRACT**

The present study demonstrated the in vitro effect of gemcitabine, taxotere, navelbine and their combination against bilharzial related bladder cancer. Tumors were explanted using the three dimensional in vitro histoculture assay with the MTT end point. All drugs were tested at their peak plasma levels. No tumor sensitivity could be detected to any of the 28 samples tested for gemcitabine with an overall in vitro response of 0 %. Among 21 samples tested for taxotere only 3 samples showed in vitro sensitivity with an overall in vitro response rate 14.28 %. Navelbine has demonstrated in vitro activity in 2 samples among 17 tested samples with an overall in vitro response rate 11.76 %. Among 14 samples tested for simultaneous application of the 3 drugs, the sensitivity of the combination was demonstrated in 1 sample and the overall in vitro response rate was 7.14 %.

There was no significant correlation between the tumor percent reduction using the different treatment and any of the clinical parameters including age, sex bilharzial affection, pathologic grade, stage and lymph node status. By comparing the tumor percent reduction among the 4 treatment groups taxotere was significantly more effective in vitro than gemcitabine. Bilharzial related bladder cancer might be more sensitive in vitro to single agents that attack microtubules than those inhibit the DNA synthesis.

The three dimensional in vitro histoculture assay with the MTT end point is a suitable in vitro chemosensitivity test that can be used if applied by others for the evaluation of the in vitro effect of different anticancer drugs singly or in combination on the bilharzial related bladder cancer.

---

# **Table Of Contents**

CHAPTER I INTRODUCTION & AIM OF THE WORK.....	1
CHAPTER II REVIEW OF LITERATURE.....	4
2.1 IN VITRO CHEMOSENSITIVITY IN THE FIELD OF ONCOLOGY .....	5
<i>Clonogenic assays:</i> .....	5
<i>Clonogenic-like assays :</i> .....	8
<i>Cell-Toxicity end-point assay :</i> .....	9
<i>Three-dimensional tissue cultures:</i> .....	11
<i>Application of Three-dimensional histocultures:</i> .....	13
2.2 CHEMOTHERAPY OF CANCER.....	15
INTRODUCTION.....	16
2.2.1 THE CELL CYCLE AND ITS IMPORTANCE: .....	19
<i>Cell cycle phase specific agents :-</i> .....	22
<i>Cell cycle phase-non specific agents:</i> .....	22
2.2.2 Classification of antineoplastic agents:.....	22
2.3 Antineoplastic drugs used in the present study.....	27
2.3.1 GEMCITABINE .....	27
2.3.2 TAXOTERE .....	30
2.3.3 NAVELBINE.....	38
CHAPTER III MATERIAL AND METHODS.....	45
STUDY DESIGN .....	46
<i>Material</i> .....	46
APPENDIX .....	50
<i>Media : Reagents and Equipment</i> .....	50
CHAPTER IV RESULTS .....	53
RESULTS OF THE IN VITRO CHEMOSENSITIVITY ASSAY : .....	56
RELATION BETWEEN IN VITRO SENSITIVITY PROFILE AND THE DIFFERENT CLINICAL PARAMETERS: .....	58
CHAPTER V DISCUSSION.....	68
SUMMARY .....	78
REFERENCES.....	82
ARABIC SUMMARY .....	95

## **List Of Tables**

<b>Table (1)</b>	55
The clinical profile of the 28 bladder cancer patients included in the study.	
<b>Table (2)</b>	57
In vitro chemosensitivity of the drugs applied on the 28 bladder cancer samples using the in vitro histoculture assay with the MTT end Point.	
<b>Table (3):</b>	60
Comparison of Tumor percent reduction using different treatment as classified by age groups.	
<b>Table (4)</b>	61
Comparison of Tumor percent reduction using different treatment as classified by sex.	
<b>Table (5)</b>	62
Comparison of Tumor percent reduction using different treatment according to bilharzial affection.	
<b>Table (6)</b>	63
Comparison of Tumor percent reduction using different treatment classified by pathology	
<b>Table (7)</b>	64
Comparison of Tumor percent reduction using different treatment classified by grade	
<b>Table (8)</b>	65
Comparison of Tumor percent reduction using different treatment classified by stage	
<b>Table (9)</b>	66
Comparison of Tumor percent reduction using different treatment classified by lymph node positivity	
<b>Table (10)</b>	67
Comparison of Tumor percent reduction among 4 treatment groups.	



---

### **List Of Figures**

<b>Fig (1)</b> Stages in the cell replication cycle	20
<b>Fig (2)</b> Chemical structure of Deoxycytidine, Gemcitabine and ara-c	27
<b>Fig(3)</b> self potentiation of Gemcitabine activity	28
<b>Fig(4)</b> Chemical structure of Docetaxel	30
<b>Fig(5)</b> Mechanism of action of Docetaxel at the microtubule level	31
<b>Fig(6)</b> Mechanism of action of Docetaxel at the cellular level	31
<b>Fig (7)</b> Chemical structure of Navelbine	38
<b>Figure (8)</b> Tumor percent reduction using different treatment as classified by age	60
<b>Fig (9)</b> Tumor percent reduction using different treatment as classified by sex	61
<b>Fig(10)</b> Tumor percent reduction using different treatment according to bilharzial affection	62
<b>Fig (11)</b> Tumor percent reduction using different treatment classified by pathology	63
<b>Fig (12)</b> Tumor percent reduction using different treatment classified by grade	64
<b>Fig (13)</b> Tumor percent reduction using different treatment classified by stage	65
<b>Fig (14)</b> Tumor percent reduction using different treatment classified by lymph node positivity	66
<b>Fig (15)</b> Tumor percent reduction among 4 treatment groups.	67

---

**INTRODUCTION**

**&**

**AIM OF THE WORK**

---

## **INTRODUCTION**

Carcinoma of bilharzial bladder is the most common cancer among Egyptian patients accounting 32% of all malignant cases presenting at the National Cancer Institute, Cairo university (*Sherif and Ibrahim, 1987*).

Radical cystectomy with urinary diversion is considered as the only curative modality so far available (*El- Sebai, 1983*). However, the overall 5 - year survival rates range only between 27%, and 39%. Also, about 25% of the cases at first presentation are advanced and not amenable to surgery.

These cases in addition to patients with non-resectable, recurrent and/or metastatic disease are potential candidates for chemotherapy.

Because bilharzial related bladder cancer is different in etiology, biology and response to chemotherapy when compared to that reported in Western countries, phase II clinical trials have been conducted since 1976 and aimed at screening various chemotherapeutic agents singly or in combination in patients with inoperable, metastatic, or recurrent bladder cancer. However, response rates and survival data are not yet satisfactory (*Gad El-Mawla et. al., 1989*). So, new ideas are still clearly needed to help in management of the most common cancer in Egypt.

At the same time, the perfection of a practical test to evaluate the efficacy of different antineoplastic drugs in the treatment of human cancer prior to the initiation of clinical chemotherapy has been an elusive goal for many investigators since the early 1950s. Recent clinical correlations of 60% accuracy for predicting a positive clinical response and 90% accuracy for predicting a lack of response to chemotherapeutic agents suggest promising clinical usefulness. There have been many attempts to design in vitro systems to determine drug response of tumors. The most widely used system is the clonogenic assay, adopted by *Salmon et al. (1984)*. However,



---

the recent development of the collagen gel assay permitted its use for malignant tissue samples rather than tumor cell suspensions (*Shimoyama et al., 1989*).

### **Aim of work**

This work was designed to check the efficacy of some new chemotherapeutic agents against bilharzial related bladder cancer in vitro in an attempt to recommend their clinical application .